NASDAQ:ENSC
READ THE FULL ENSC RESEARCH REPORT
Ensysce Biosciences (NASDAQ:ENSC) released its 2Q 2024 report and reiterated the positive results seen throughout the first half of the year and looked ahead to an important second half. Importantly, the company announced that it expected the Phase 3 clinical trial for PAR614 to be initiated in the second half of 2024. Given the results seen in the testing to this point, which we have written extensively about, we are excited to get the Phase 3 testing phase started and expect further positive outcomes that will be a major step toward commercialization and relief many patients need.
We aren’t going to rehash recent reports that have outlined the positive test results for PF614 and PF614-MPAR. But, as a reminder, these tests have shown that PF614 can provide the much-needed pain relief that is currently available through the highly abused oxycodone, while having abuse resistant properties and lasting longer. Additionally, an important reminder that PF-614-MPAR received an FDA grant of Breakthrough Therapy designation, which allows ENSC the opportunity to accelerate clinical programs and commercialization plans. The grant, which has been applied to fewer than 300 drugs historically, illustrates the importance and urgency that these solutions are needed. We are again reiterating our belief that the treatments being developed by Ensysce will be game changers in the pain relief market and again suggest that investors take a strong look at ENSC.
PF614-MPAR has been shown in testing to have the potential to provide much needed pain relief to patients and provides protections against taking too many pills, which often leads to debilitating addiction. The technology involved causes the drug to become inactive when dosing requirements are exceeded—greatly diminishing the “incentive” patients may have to take more than the prescribed dose.
Ensysce Biosciences continues to be one of the companies that we cover that we believe most of America would hope is successful and one we are becoming more convinced will achieve its goals. The opioid crisis remains a plague on the American public and is destroying families and entire communities. The National Institute on Drug Abuse reported more than 107,000 overdose deaths in 2022—and that doesn’t count the millions of family members and friends impacted by those deaths. Ensysce has extremely promising technology in the form of PF614 and PF614-MPAR that are abuse resistant, while still providing the much-needed pain relief that many Americans need with a longer lasting dose than its bioequivalent OxyContin.
The company also outlined its progress in helping people that are already suffering from opioid use with the Opioid Use Disorder (OUD) program. The lead drug candidate for this program is known as PF9001 and the company announced an exciting breakthrough regarding the treatment. Management revealed that PF9001, designed with the application of Ensysce’s TAAP platform to reduce the abuse profile, has demonstrated a lower potential for cardiovascular side effects associated with traditional methadone OUD treatments. The company also noted that the program is continuing to advance to Investigational New Drug (IND) enabling studies. Management also noted that the OUD work has been supported by a multi-year Helping to End Addiction Long-Term (HEAL) award of up to $15 million granted by the NIH and the National Institute on Drug Abuse.
We have written for some time how important the work ENSC is doing is and continue to believe that. We also believe that investors who invest in such important work have the potential to be rewarded quite well as these solutions to a problem plaguing thousands of families come to fruition. We encourage investors to take a look at ENSC and consider the stock before the anticipated positive testing results come in.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
